Phase III trial results favour lanreotide therapy in patients with gastroenteropancreatic neuro-endocrine tumours

A strong anti-proliferative response was demonstrated for the somatostatin analogue lanreotide in patients with gastroenteropancreatic neuro-endocrine tumours. The final analyses of data from a phase III trial showed that treatment with lanreotide significantly prolonged progression-free survival in patients with gastroenteropancreatic neuroendocrine tumours compared to treatment with placebo. Read more here.